Clinical trial · Observational
90-Day Mortality After Emergency Department Discharge in Advanced Cancer
Evaluation of Factors Affecting 90-Day Mortality After Emergency Department Discharge in Patients With Advanced Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective observational study investigates factors associated with 90-day mortality among patients with advanced cancer who present to the emergency department (ED). The study will include stage IV solid tumor patients who visited the ED of Etlik City Hospital between December 2022 and March 2025. Demographic, clinical, and laboratory parameters such as performance status, nutritional and inflammatory markers, and biochemical values will be analyzed. The primary objective is to identify prognostic indicators that predict short-term mortality following ED visits. By establishing risk profiles, the study aims to optimize patient triage, guide timely referral to supportive and palliative care services, and improve overall care strategies for advanced cancer patients in acute settings.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Emergency Department Admission | — | UNRESOLVED | — |
| Metastatic Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Mortality | — | UNRESOLVED | — |
| Oncology | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Retrospective Data Collection and Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Advanced Cancer Patients Presenting to the Emergency Department
- description
- This retrospective cohort includes adult patients (≥18 years) with pathologically confirmed stage IV solid tumors who presented to the emergency department of Etlik City Hospital between December 2022 and March 2025. Patients were eligible if they had received systemic anticancer therapy within the previous 6 months and had complete clinical and laboratory records. Both patients discharged from the ED and those who were admitted or died during the ED visit are included. Data collected include demographic characteristics, performance status, primary tumor type, metastatic sites, reasons for ED admission, laboratory values, and subsequent outcomes. The cohort will be analyzed to identify prognostic factors associated with 90-day mortality, ED re-admissions, and re-hospitalizations.
- interventionNames
- Other: Retrospective Data Collection and Analysis
Primary outcomes (1)
- measure
- 90-Day All-Cause Mortality After Emergency Department Visit
- timeFrame
- 90 days after emergency department visit
- description
- All-cause mortality within 90 days following presentation to the emergency department among patients with stage IV solid tumors. Mortality status will be confirmed using the hospital information system (HBYS) and the national death registry (e-Nabız). Both in-hospital and out-of-hospital deaths will be included.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Pathologically confirmed stage IV (metastatic) solid malignancy * Followed at Etlik City Hospital, Department of Medical Oncology * Presented to the emergency department between December 2022 and March 2025 * Either discharged on the same day, admitted to the hospital, or died during the ED visit * Received systemic anticancer therapy (chemotherapy, immunotherapy, targeted therapy, or hormonal therapy) within the past 6 months * Availability of complete clinical and laboratory data Exclusion Criteria: * Stage I-III cancer patients * Patients not receiving systemic therapy, only palliative/supportive care * Patients followed in other oncology centers but presenting to Etlik City Hospital ED * Patients with hematologic malignancies (e.g., leukemia, lymphoma, multiple myeloma) * Patients with missing clinical or laboratory data
References
Publications (0)
Data not yet available